Regenerative Medicine Advanced Therapy

CAR-T therapy
#CAR-T #Cell therapy #FDA #Kyverna Therapeutics #Regenerative Medicine Advanced Therapy

Kyverna receives advanced therapy designation for KYV-101

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutic’s CAR-T candidate KYV-101 for refractory stiff-person syndrome (SPS). KYV-101 is an autologous, fully human CD19 CAR-T cell product candidate for use in B cell-driven autoimmune diseases. The RMAT designation was based on… Read More

#News #Regulatory